1-5 of 5
Markus Wartmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PR007: Discovery of HRO761, a novel, first-in-class clinical stage WRN inhibitor with potent and selective anti-tumor activity in cancers with microsatellite instability

Free
Marta Cortes-Cros, Henrik Moebitz, Stephanie Barbe, Jutta Blank, Vincent Bordas, Giorgia Clementi, Ernesta Dammassa, Andrea Decker, Noemi Di Nanni, Ruben de Kanter, Marion Dourdoigne, Elena Gavioli, Stephane Ferretti, Marc Hattenberger, Christelle Hemmerlin, Jacques Hamon, Juergen Hinrichs, Isabel Jaco, Dragana Jankovic, Eloisa Jimenez Nunez, Yifang Li, Hans-Joerg Martus, Michele Moschetta, Cornelia Quadt, Markus Reschke, Vincent Romanet, Clemens Scheufler, Joseph Schoepfer, Ross Strang, Maxime Therier, Hans Voshol, Markus Wartmann, Sarah Welly, Monica Pham, Laurent Laborde
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): PR007.
https://doi.org/10.1158/1535-7163.TARG-23-PR007
Published: 01 December 2023
View articletitled, Abstract PR007: Discovery of HRO761, a novel, first-in-class clinical stage WRN inhibitor with potent and selective anti-tumor activity in cancers with microsatellite instability
Journal Articles

FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer

Free
Andreas Weiss, Flavia Adler, Alexandra Buhles, Christelle Stamm, Robin A. Fairhurst, Michael Kiffe, Dario Sterker, Mario Centeleghe, Markus Wartmann, Jacqueline Kinyamu-Akunda, Heiko S. Schadt, Philippe Couttet, Armin Wolf, Youzhen Wang, Patrizia Barzaghi-Rinaudo, Masato Murakami, Audrey Kauffmann, Thomas Knoepfel, Nicole Buschmann, Catherine Leblanc, Robert Mah, Pascal Furet, Jutta Blank, Francesco Hofmann, William R. Sellers, Diana Graus Porta
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2194–2206.
https://doi.org/10.1158/1535-7163.MCT-18-1291
Published: 02 December 2019
View articletitled, FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Open the PDF for FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A140: Evaluation of prediction of in vivo activity from in vitro combinations: Examples using a MEK1/2 inhibitor combined with docetaxel in NSCLC models.

Free
Paul Martin J. Mcsheehy, Alex Cao, Giordi Caponigro, David Duhl, Brant Firestone, Tom Gesner, Daniel Guthy, Jocelyn Holash, Fred King, Joseph Lehar, Christopher Leroy, Manway Liu, Lilli Petruzzelli, Dale Porter, Daniel Menezes, Anupama Reddy, Johannes Roesel, Christian Schnell, Timothy Smith, Mark Stump, Markus Wartmann, Marion Wiesmann
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A140.
https://doi.org/10.1158/1535-7163.TARG-13-A140
Published: 01 November 2013
View articletitled, Abstract A140: Evaluation of prediction of in vivo activity from in vitro combinations: Examples using a MEK1/2 inhibitor combined with docetaxel in NSCLC models.
Journal Articles

Abstract B246: NVP-BGJ398: A potent and selective inhibitor of the fibroblast growth factor receptor family.

Free
Vito Guagnano, Diana Graus Porta, Vincent Bordas, Mickael Le Douget, Christelle Stamm, Pascal Furet, Carsten Spanka, Markus Wartmann, Herbert Schmid, Josef Brueggen, Peter Drueckes, Dirksen Bussiere, Tinya Abrams, Katherine Rendahl, Isabelle Bernard-Pierrot, Francois Radvanyi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B246.
https://doi.org/10.1158/1535-7163.TARG-11-B246
Published: 12 November 2011
View articletitled, Abstract B246: NVP-BGJ398: A potent and selective inhibitor of the fibroblast growth factor receptor family.
Journal Articles

Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805

Free
Fabienne Baffert, Catherine H. Régnier, Alain De Pover, Carole Pissot-Soldermann, Gisele A. Tavares, Francesca Blasco, Josef Brueggen, Patrick Chène, Peter Drueckes, Dirk Erdmann, Pascal Furet, Marc Gerspacher, Marc Lang, David Ledieu, Lynda Nolan, Stephan Ruetz, Joerg Trappe, Eric Vangrevelinghe, Markus Wartmann, Lorenza Wyder, Francesco Hofmann, Thomas Radimerski
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (7): 1945–1955.
https://doi.org/10.1158/1535-7163.MCT-10-0053
Published: 07 July 2010
View articletitled, Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
Open the PDF for Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805 in another window
Includes: Supplementary data